Abstract 1152P
Background
Somatostatin-receptor (SSTR)-targeted-PET/CT is widely used for diagnosis and disease monitoring of pheochromocytoma / paraganglioma (PPGLs). The aim of this study was to assess the potential of the novel SSTR-targeted tracer [18F]-SiTATE in diagnosing PPGLs by comparing imaging parameters to tumor marker levels and secretory activity in a small cohort of patients diagnosed with this rare tumor type.
Methods
All patients with histologically confirmed PPGL presenting for [18F]-SiTATE-PET/CT at LMU Klinikum between 10/2020 and 02/2024 as well as hormonal laboratory analysis of both plasma and 24-hour urine samples within up to 100 days were included. Metabolic tumor volume (MTV) was assessed using a threshold of mean standard uptake value (SUVmean) of 5.0. Total lesion uptake (TLU) was assessed with SUVmean x MTV. Correlation was tested using spearmanś rank correlation test.
Results
34/39 patients (median age: 55, range: 5-83) were included in this study. 5 patients with cervical PGL were excluded. 21 patients had metastatic disease. There was a moderate correlation between TLU and MTV and urinary dopamine (r=0.50-0.51, p<0.05) as well as norepinephrine (r=0.50-0.54, p<0.05). TLU and MTV correlated moderately with serum chromogranin-A levels (r= 0.60, p<0.01, respectively). A moderate correlation was determined between TLU and MTV with plasma normetaphrine and 3-Methoxytyramine (r=0.52-0.56, p<0.01).
Conclusions
MTV and TLU measured with [18F]-SiTATE-PET/CT correlate well with the tumor marker chromogranin-A in serum and with particular biomarkers of the catecholamine pathway in urine and plasma, reflecting metabolic tumor activity. Within the limits imposed by the relatively small cohort, our results suggest that TLU in [18F]-SiTATE-PET/CT could be used as imaging biomarker for monitoring of disease progression and secretory activity in patients with PPGL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
498P - Report of 9 cases of embryonal tumours of the central nervous system with multilayered rosettes (ETMR)
Presenter: Ruyu Ai
Session: Poster session 17
Resources:
Abstract
499TiP - A phase II study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy
Presenter: Brian Stockdale
Session: Poster session 17
500TiP - Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Presenter: Michael Weller
Session: Poster session 17
501TiP - Clinical performance evaluation of a brain cancer liquid biopsy
Presenter: James Cameron
Session: Poster session 17
692P - Role of adjunctive surgery after platinum-based chemotherapy in management patients with adrenocortical carcinoma: Observation study
Presenter: Yaroslav Zhulikov
Session: Poster session 17
693P - Causes of death in patients with malignant adrenal tumors: A population-based analysis
Presenter: Shangqing Ren
Session: Poster session 17
946P - Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior atezolizumab and bevacizumab treatment: A multicenter retrospective study
Presenter: Jung Sun Kim
Session: Poster session 17
948P - Drug type and duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors (PREVENT): An update analysis of a prospective, multicentric cohort study
Presenter: Jia-Yong Su
Session: Poster session 17
Resources:
Abstract
949P - Update results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection
Presenter: Xianhai Mao
Session: Poster session 17
950P - Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
Presenter: Masatoshi Kudo
Session: Poster session 17